| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Savara Inc. | Molgradex - OPTIMA | Nontuberculous mycobacteria (NTM) | Phase 2a | Trial Completed | Inhalation | Antibiotic |
| Scholar Rock Holding Corporation | Apitegromab - (OPAL) | Spinal muscular atrophy (SMA) | Phase 2 | Trial Planned | Intravenous | Genetic Disorder |
| Scholar Rock Holding Corporation | SRK-439 with apitegromab - (EMBRAZE) | Obesity | Phase 2 | Ongoing | Intravenous | Endocrinology |
| Scholar Rock Holding Corporation | Apitegromab (SRK-015) - (TOPAZ) | Spinal muscular atrophy (SMA) | Phase 2 | Ongoing | Intravenous | Genetic Disorder |
| Scilex Holding Company | ELYXYB | Acute pain indication | sNDA Filing | Ongoing | Oral | Non-Opioid Analgesic |
| Scilex Holding Company | SP-103 (lidocaine topical system) 5.4% | Chronic neck pain associated with muscle spasms | Phase 3 | Trial Planned | Topical | Non-Opioid Analgesic |
| Scilex Holding Company | SP-102 | Lumbar Radicular, Sciatica Pain | Phase 3 | Trial Planned | Epidural injection | Orthopedic |
| Scilex Holding Company | KDS2010 | Alzheimer's disease | Phase 2 | Ongoing | Oral | Neurology |